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Abstract
Introduction The aim of this study was to determine a low
disease activity threshold - a 28-joint disease activity score
(DAS28) value - for the decision to maintain unchanged
disease-modifying antirheumatic drug (DMARD) treatment in
rheumatoid arthritis patients, based on expert opinion.
Methods Nine hundred and sixty-seven case scenarios with
various levels for each component of the DAS28 (resulting in a
disease activity score between 2 and 3.2) were presented to 44
panelists. For each scenario, panelists had to decide whether or
not DMARD treatment (excluding steroids) could be maintained
unchanged. In each scenario, for decision, the participants were
given the DAS28 parameters, without knowledge of the
resultant DAS28. The relationship between panelists' decision,
DAS28 value, and components of the score were analysed by
multiple logistic regression analysis. Each panelist analysed 160
randomised scenarios. Intra-rater and inter-rater reproducibility
were assessed.
Results Forty-four panelists participated in the study. Inter-
panelist agreement was good (κ = 0.63; 95% confidence
interval = 0.61 to 0.65). Intra-panelist agreement was excellent
(κ = 0.87; 95% confidence interval = 0.82 to 0.92). Quasi-
perfect agreement was observed for DAS28 ≤ 2.4, less
pronounced between 2.5 and 2.9, and almost no agreement for
DAS28 > 3.0. For values below 2.5, panelists agreed to
maintain unchanged DMARDs; for values above 2.5,
discrepancies occurred more frequently as the DAS28 value
increased. Multivariate analysis confirmed the relationship
CI: confidence interval; DAS28: 28-joint disease activity score; DMARD: disease-modifying antirheumatic drug; ESR: erythrocyte sedimentation rate; 
OMERACT: Outcome Measures in Rheumatoid Arthritis Clinical Trials; PASS: patient acceptable symptom state; RA: rheumatoid arthritis; RAPID: 
routine assessment of patient index data; STPR: stratégie thérapeutique de la polyarthrite.Arthritis Research & Therapy    Vol 11 No 5    de Bandt et al.
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between panelist's decision, DAS28 value and components of
the DAS28. Between DAS28 of 2.4 and 3.2, a major
determinant for panelists' decision was swollen joint count.
Female and public practice physicians decided more often to
maintain treatment unchanged.
Conclusions As a conclusion, panelists suggested that in
clinical practice there is no need to change DMARD treatment
in rheumatoid arthritis patients with DAS28 ≤ 2.4.
Introduction
The aim of rheumatoid arthritis (RA) treatment is remission.
The combination of new potent treatments, early intervention,
and a treatment strategy of tight control makes remission a
daily possibility [1-3]. In clinical practice, active disease means
that clinicians will increase the treatment to obtain remission;
but that also means that clinicians can stop, add to or increase
treatments once the goal is achieved. What is the level of
activity to amend treatment?
Even with a combination of multiple therapeutic agents, drug-
induced remission is difficult to reach as Pinals criteria [4] are
difficult to achieve in clinical trials, even when using the most
potent new drugs. A better alternative might therefore be to
change the remission criteria to other criteria.
For this purpose a new therapeutic goal has been proposed.
A state of near remission or partial remission, or of minimal dis-
ease activity or low disease activity, has been proposed in
recent years, to be used in clinical trials or guidelines with new
disease-modifying antirheumatic drug (DMARD) treatments
arriving on the market in the 2000s [3,5-11].
This area of low disease activity might be limited by two thresh-
olds, an upper threshold and a lower threshold, which are set
to help the treatment decision. The upper threshold of disease
activity is the level above which treatment prescription in naïve
patients or a switch/intensification in previously treated
patients is needed and strongly recommended, and the lower
threshold is the level below which treatment maintenance
could be recommended; some uncertainties remain for practi-
cal issues between these two thresholds.
Persistence of moderate to high disease activity (whatever the
measurement criteria we use) is the usual standard to decide
whether treatment should be considered ineffective and
patients should be switched to another treatment. But on the
contrary, when treatment is effective, even with persistence of
some degree of low disease activity, the question remains how
to decide whether it is worth not changing and better maintain-
ing current treatment, to spare further resources.
Several disease activity measures are currently available, and
indices such as the 28-joint disease activity score (DAS28) or
derivates are currently used for such decisions at the upper
bound. Usually DAS28 > 3.2 is accepted to consider the dis-
ease active enough and to reinforce the treatment dosage or
to switch the DMARD [5-12]. On the contrary, DAS28 < 2.4
defines remission, but there is no recommendation telling the
clinician what to do once this level is reached.
Some uncertainties still remain in defining the lower threshold
below which treatment maintenance could be recommended.
The first uncertainty is that there is no agreement on the best
tool to be used to define this state of near remission. Practi-
cally, the DAS28 remains the most used in clinical practice
and has been validated is trials - with some areas of uncer-
tainty below the threshold of indication for changing therapy
(3.2) and around the level of remission (2.6) as proposed by
the DAS28 designers. The second issue is that the definition
of such low disease activity implies the recognition of a thresh-
old value of activity under which the disease could be consid-
ered low enough to keep treatment unchanged (except
steroids), and therefore serves as a basis for clinicians to main-
tain unchanged the treatment.
As everyday practice is different from clinical trials, we aimed
to determine such a threshold based on the expert physicians'
decision method and to develop recommendations for clini-
cians to use the DAS28 in clinical practice in the area of
uncertainty (DAS28 of 2 to 3.2), in order to guide the decision
to maintain unchanged or to not maintain a DMARD treatment;
that is, to avoid changing because of sufficient/acceptable
effectiveness.
The present study was designed to determine a low disease
activity threshold - that is, a DAS28 value - below which
DMARD treatment should not be changed in RA patients.
Materials and methods
Design
The present survey was conducted using paper case scenar-
ios of patients with various levels of disease activity presented
to rheumatologists in public and private practice.
Sample
The stratégie thérapeutique de la polyarthrite (STPR) initiative
is a group of rheumatology experts from French university hos-
pitals (public) working on implementation of practical guide-
lines for therapeutic strategy in RA [13-15]. Each STPR expert
recruited rheumatologist physicians with exclusive private or
public practice or with combined practice among rheumatolo-
gists trained by the STPR group in each region of France to
understand and implement current recommendations of treat-
ment. A group of 44 panelists was constituted for this work.Available online http://arthritis-research.com/content/11/5/R157
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Case scenarios
Virtual scenarios were constructed on a distribution of DAS28
values (four variables) in steps of 0.1 from 2.0 to 3.2 - chosen
to be below the proposed threshold of indication for changing
therapy (3.2) and around the level of remission (2.6) [1-3] -
among all possible combinations of DAS28 parameters: eryth-
rocyte sedimentation rate (ESR), patient global activity,
number of swollen joints, and number of tender joints.
To limit the number of possible scenarios with all possible
combinations resulting in DAS28 values within the range of
2.0 to 3.2, it was decided to increment the DAS28 by 0.1
points for assessment of disease activity, by 5 points from 10
to 50 for the ESR (mm/hour), and by 1 point from 0 to 28 for
the number of tender joints and for the number of swollen
joints, thus constituting 967 case scenarios.
All case scenarios were presented considering that RA activity
had been stable for the past 3 months. The participants were
given the DAS28 parameters, without knowledge of the result-
ant DAS28 value. For example, a scenario corresponding to a
DAS28 of 's' (not provided to the respondent) was 'In this
patient with clinical status stable since 3 months with ESR =
x, number of tender joint = y, number of swollen joint = z and
global assessment of disease activity = t, would the level of
disease activity be considered low enough for maintaining the
current DMARD therapy (except steroids that were not con-
sidered as DMARDS in this work) without changing neither
molecule nor dose regimen? Answer: Yes or No.'
Interviewees were instructed to consider this clinical status,
without any specific joint involvement and whatever the current
therapy, including corticosteroid or not, and were not asked to
calculate the disease activity score.
Reproducibility design
Intra-panelist reproducibility and inter-panelist reproducibility
were assessed and the determinant of decision was analysed.
Inter-rater reproducibility was evaluated. A first set of 60 sce-
narios in the range 2.0 to 3.2 (five scenarios in each of the 12
steps of 0.1) was obtained randomly and submitted to the 13
STPR experts. The total 60 scenarios were presented in ran-
dom order, and were answered by self-administration.
Intra-rater reliability was evaluated during the next step (survey,
see below). A set of 12 scenarios was randomly selected
among the 967 cases. The scenarios were duplicated and
these 24 scenarios were mixed randomly within all the scenar-
ios submitted to the panelists.
Survey
All panelists were asked to rate the 967 case scenarios. In
order to increase the feasibility, it was decided that partici-
pants would not have to rate all scenarios. Therefore 184 sce-
narios were given to every participant; that is, 160 out of 955
(967 - 12) scenarios were randomly attributed, which differed
from one rheumatologist to another (each random choice con-
ducted using the proc plan procedure in SAS software; (SAS
Software, Cary NC, USA), and were mixed with the 24 (12 ×
2) scenarios described above for evaluation of intra-rater
reliability.
A research nurse conducted the rating interview with the pan-
elist on the telephone as a support. Panelists and nurses had
the same material of case scenarios available. The survey was
completed within a 4-week period from May to June 2007.
Statistical analysis
Reproducibility analysis
Inter-panelist reliability was assessed by the multirater κ coef-
ficient [16] and its 95% confidence interval (CI), which ranges
from 0 to 1 and rates the agreement between raters as low (<
0.2), fair (0.2 to 0.4), moderate (0.4 to 0.6), good (0.6 to 0.8)
or excellent (> 0.8).
Results are also presented considering perfect agreement
(restricted to all experts making the same decision) and con-
sidering quasi-perfect agreement (accepting 80% of experts
making the same decision). The determinants of agreement
between panelists among the components of the DAS28 were
sought by logistic regression analysis of perfect agreement
and of quasi-perfect agreement. Odds ratios were considered
significant at α = 0.05.
Intra-panelist reliability was assessed by Cohen's κ coefficient
for agreement. The probability (odds ratio) of determinants of
agreement within panelists was assessed using logistic
regression.
Determining threshold for treatment maintenance
The proportion of panelists' opinions to maintain or change
treatment regimen was expressed as a mean percentage of
answers to scenarios at each step of the DAS28 value.
The determinants of the decision to change the treatment reg-
imen were further analysed in a logistic regression model
where odds ratios were considered significant at α = 0.05.
This analysis was conducted over all answers to scenarios and
was replicated in each group of scenario by steps of 0.1
points of DAS28 values. Because the number of case scenar-
ios increased by category, a subset of 310 answers to scenar-
ios was randomly selected in each step category to allow
similar comparison of model results and interpretation in terms
of power and significance of the conclusion reached.
All analyses were conducted under SAS software version 9.1.Arthritis Research & Therapy    Vol 11 No 5    de Bandt et al.
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The results of the whole analysis were then examined by the
STPR group in order to edit recommendations for the decision
to maintain DMARD treatment unchanged in RA patients.
Results
Experts
A total of 44 panelists participated in the study, including 13
experts or members from the STPR group. They were on aver-
age 43 ± 6.6 years old, 38% were female, and they obtained
their certification as rheumatologists on average 17 ± 6.3
years ago. The panelists' clinical activity was university public
hospital (65%) or private practice (35%).
Inter-panelist reliability and intra-panelist reliability
Among the 60 scenarios presented to panelists, 59 were filled
in by the 13 experts of the STPR group and the agreement
reached a κ value of 0.63 (0.61 to 0.65). The κ value
increased to 0.69 (0.65 to 0.73) and 0.76 (0.72 to 0.80) when
restricting the analysis to the 12 most concordant and the 11
most concordant panelists, respectively.
Further reduction did not modify κ values meaningfully. The
inter-rater agreement was therefore good. Figure 1 shows the
distribution of cases by DAS28 value with quasi-perfect
agreement over a value of 2.6.
The probability of inter-panelist quasi-perfect agreement was
significantly higher when the patient global evaluation of activ-
ity, the ESR and the number of swollen joints were higher
(Table 1).
Intra-rater reliability was excellent, with a κ value of 0.83 (95%
CI = 0.78 to 0.88).
Threshold for treatment maintenance
The decision to maintain treatment was analysed from 7,224
answers. Figure 2 shows the proportion of cases by category
of DAS28 value with the decision to maintain treatment. Pan-
elists were in quasi-agreement to make a decision to maintain
treatment in more than 80% of cases for DAS28 < 2.4,
decreasing to 70% until a DAS28 value of 2.6, and then
around 60% from DAS28 > 2.9.
Overall, all DAS28 components were significant determinants
of the decision to maintain treatment unchanged (Table 2).
Higher patient global assessment of disease activity, ESR,
number of tender joints and number of swollen joints reduced
significantly the likelihood of the decision to maintain treatment
unchanged. For instance, a patient with global activity of 15,
ESR of 10, no tender joint and 22 swollen joints would have a
probability of treatment being unchanged of 2.54%. If one of
each parameter increased by one unit, this would result in a
lower probability of 2.48% with global activity of 16, a proba-
bility of 2.43% with ESR of 11, and a probability of 2.04% with
23 swollen joints or one tender joint.
Between DAS28 values of 2.4 and 3.2, each category increas-
ing by 0.1 (310 randomly selected answers), the various
regression analyses of the decision to change treatment
showed that the major determinant for the panelists' decision
to maintain treatment unchanged was the lower number of
swollen joints (odds ratio from 0.4 (DAS28 between 2.4 and
2.5) to 0.7 (DAS28 between 3.0 and 3.1)).
Female (64% vs. 56%, P = 0.0002) and public practice phy-
sicians (61% vs. 50%, P < 0.0001) decided more often to
maintain treatment unchanged. Decisions were not signifi-
cantly related to panelists' characteristics of age (P = 0.6825)
and year of diploma (P = 0.1124).
Figure 1
Proportion of quasi-perfect agreement according to 28-joint disease activity score Proportion of quasi-perfect agreement according to 28-joint disease activity score. Distribution of cases by 28-joint disease activity score (DAS28) 
value (incremented in steps of 0.1 from 2.0 to 3.2) and the percentage of quasi-perfect agreement decreasing over a DAS28 value of 2.6.Available online http://arthritis-research.com/content/11/5/R157
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Discussion
The present study has evidenced some major findings. The
discordance in the decision to maintain or change treatment
lies within the range of 2.5 to 3.2 for the DAS28 value, sug-
gesting setting a consensual threshold of 2.4 to define main-
tenance of treatment. Second, panelists make the decision to
maintain DMARD treatment (excluding steroids) with excellent
intra-rater reliability, but only moderate to good inter-rater reli-
ability. Also, determinants of the decision have been evi-
denced with remarkable persistence whatever the level of
disease activity in this range; namely, the ESR level, the
patient's global activity, the number of tender joints and the
number of swollen joints are taken into consideration by
experts to make their decision. Fourth, these results are inde-
pendent of experts' characteristics of age, sex, and year of
diploma, but not of type of practice. Finally, according to these
results, panelists concluded that in clinical practice there is no
need to change DMARD treatment (neither molecule nor dose
regimen) when a patient with stable clinical status over the
past 3 months has DAS28 ≤ 2.4.
Targeting remission is recommended given recent changes
and innovations in therapy as well as the evolution of therapeu-
tic strategies. There is no general consensus, however,
regarding definition of remission. Achieving Pinals criteria (five
out of six criteria: morning stiffness absent or not exceeding 15
minutes, no fatigue, no joint pain by history, no joint tender-
ness, no joint or tendon sheath swelling, and no elevation of
the ESR) was estimated to be rare in the 1990s [4,10,11].
Moreover, Pinals criteria are difficult to apply in clinical trials.
Table 1
Determinants of inter-panelist perfect and quasi-perfect agreement
Perfect agreement Quasi-perfect agreement
Odds ratio 95% confidence interval Odds ratio 95% confidence interval
Patient global assessment of disease activity 1.01 0.97 to 1.05 1.06 1.01 to 1.12
Erythrocyte sedimentation rate 1.05 0.99 to 1.12 1.15 1.04 to 1.27
Number of tender joints 0.88 0.41 to 1.88 3.00 1.23 to 7.31
Number of swollen joints 0.99 0.88 to 1.11 -a
The probability of inter-panelist perfect agreement was significantly higher when the patient global evaluation of activity, erythrocyte sedimentation 
rate and number of swollen joints were higher. aNot included in the model because of quasi-complete separation of the data point.
Figure 2
Decision to maintain/change treatment according to 28-joint disease activity score Decision to maintain/change treatment according to 28-joint disease activity score. Proportion of cases by category of 28-joint disease activity score 
(DAS28) (range 2.0 to 3.2) analysed with a decision to maintain the treatment from 7,224 answers. Panelists were in quasi-agreement to make a 
decision to maintain treatment in more than 80% of cases for DAS28 < 2.4, decreasing to 70% until a DAS28 of 2.6, and around 60% for DAS28 
> 2.9.Arthritis Research & Therapy    Vol 11 No 5    de Bandt et al.
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The use of different definitions of RA remission leads to differ-
ent results with regard to remission rates. Analysis of a data-
base of more than 5,800 RA patients showed that the overall
remission rate was lowest using the American College of
Rheumatology definition of remission (8.6%), followed by the
clinical disease activity index (13.8%) and routine assessment
of patient index data (RAPID) 3 (14.3%) definitions; the rate
was highest when remission was defined using the DAS28
(19.6%) [17].
Using the disease activity score, a state of near remission has
been proposed recently [3,5,10,11] with two thresholds to
help the treatment decision: an upper threshold of disease
activity, above which intensification is recommended; and a
lower threshold, below which treatment maintenance can be
recommended. Usually, DAS28 > 3.2 is accepted to consider
the disease active enough and to reinforce the treatment dos-
age or to switch DMARD [8]. The lower bound is less obvious
and has been investigated using several methods [5-10]: the
DAS28 value, the OMERACT definition, the patient accepta-
ble symptom state (PASS) or the RAPID score (patient index
data scores)
The value of 2.6 has been proposed by developers of the
DAS28 [12]. After calculating the disease activity of patients
included in a cohort as well as a modification of the American
Rheumatology Association definition for clinical remission,
receiver operating characteristic analysis was used to deter-
mine the cut-off point with maximum sensitivity and specificity
in the DAS28 corresponding with fulfillment of the modified
American College of Rheumatology criteria. The optimal cut-
off value corresponding to American College of Rheumatology
criteria for remission was 2.66 [7].
The disease activity score has been criticised for its perform-
ances in the spectrum of a low level of disease activity
[11,18,19]. We found that panelists were in good agreement
below a score of 2.5. Over this threshold, other data may be
requested and may actually be fully incorporated in clinical
practice judgment. Other patient-reported outcomes, in addi-
tion to the global patient assessment component, are also
important to consider in weighing up the consequences of
activity.
One limitation of the disease activity score remains that it does
not specify whether swollen joints are ankles or metatar-
sophalangeal joints, possibly resulting in some unbalanced
estimate of activity.
The OMERACT defined minimal disease activity as patients
with no tender or swollen joints and ESR < 10 [20]. If this def-
inition is not reached, patients must have either a DAS28 value
≤ 2.85 or meet five among seven criteria (pain ≤ 2, health
assessment questionnaire score ≤ 0.3, tender joint count ≤ 1,
swollen joint count ≤ 1, patient global activity ≤ 2, physician
global activity ≤ 1.5, ESR ≤ 20).
As low disease activity is closely related to treatment decision-
making, others have proposed to define a minimal clinically
important improvement and a PASS. The concept of PASS
translates the response at the group level (change in mean
scores) into clinically meaningful information by addressing
the patient level as therapeutic success (yes/no) in order to
help the decision. The concept is not fully formulated at the
present time [21,22].
Pincus and colleagues proposed a continuous quality
improvement approach to assess and manage RA patients
without formal joint counts, based on quantitative RAPID
scores on a multidimensional health assessment questionnaire
[23].
Furst and colleagues, using expert opinion and the Research
and Development/University of California in Los Angeles
(RAND/UCLA) Appropriateness Method, have proposed
recently to consider that only the clinically active joint count
should be considered the most important decision factor
among a literature review of various outcome measures [24].
Among 108 scenarios developed to simulate various clinical
situations, the panelists recommended that the clinically active
joint count should be the most important decision factor, and
in patients with no active joints they recommended that,
Table 2
Determinants of maintaining treatment unchanged
Odds ratio 95% confidence interval P value
Patient's global assessment of disease activity 0.15 0.11 to 0.21 < 0.0001
Erythrocyte sedimentation rate 0.49 0.37 to 0.65 < 0.0001
Number of tender joints 0.34 0.23 to 0.49 < 0.0001
Number of swollen joints 0.004 0.003 to 0.005 < 0.0001
Interaction (number of tender joints × number of swollen joints) 2.06 1.51 to 2.82 < 0.0001
Determined using multivariate logistic regression, n = 7,224. Overall, all 28-joint disease activity score (DAS28) components are significant 
determinants of the decision to maintain treatment unchanged. All variables are transformed according to the DAS28 formula.Available online http://arthritis-research.com/content/11/5/R157
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regardless of other factors, treatment should not be changed.
Patients with five or more active joints were considered inade-
quately treated, patients with no active joints had no need to
change therapy, and in patients with one to four active joints
other variables must be considered.
As some uncertainty still remains, we aimed to determine such
a threshold based on the experts' decision method and to
develop recommendations for clinicians in order to guide the
decision to maintain unchanged or not a DMARD treatment;
that is, to avoid changing because of sufficient/acceptable
effectiveness. In this particular area below the threshold of
indication for changing therapy (3.2) and at about the level of
remission (2.6), we have shown that determinants of the deci-
sion have been evidenced with remarkable persistence what-
ever the level of disease activity in this range - namely, the ESR
level, patient's global assessment of disease activity, number
of tender joints and number of swollen joints are taken into
consideration by experts to make their decision. The impor-
tance of patient-reported outcomes is now clearly acknowl-
edged, and our results value both patients' and physicians'
criteria.
Development of recommendations for clinical practice may
use various methodologies and be data driven or expert driven.
Elicitation of expert opinion uses the Delphi method, focus
groups, consensus, and so forth. The data-driven methodol-
ogy (DAS28) is based on the data observed and retrospec-
tively analysed. The data are inherently subjected to indication
bias (that is, results are dependent on the initial decision of
treatment), which is driven by initial judgment of patient status
- while expert opinions are dependent on the experts' choice
(that is, representativity of experts is sometimes questionable).
This latter observation may have some advantage in term of
ease to collect data. Expert opinion is now largely developed
and accepted as an alternative to produce consensus and
informed decision.
One strength of the present work is that the judgments made
were unbiased. The OMERACT method is largely used for
reaching consensus, with its validated threshold proposed in
the literature [21]. Our approach, however, asked experts to
make their judgment without knowing the DAS28 value of sce-
narios - therefore, independently.
One important limitation of the present work is that it does not
consider the long-term effect of maintaining low disease activ-
ity. Recent works have shown that even if patients are main-
tained under highly effective treatment, with low disease
activity, the long-term deterioration of the joint continues to
progress, tempering the enthusiasm of the new class of bio-
logic agents. But in the context of spare resources, the aim is
still to preserve the future possibility of action.
Another possible limitation is that we did not consider steroids
as DMARDs, even if in light of recent data this opinion should
be modified in the near future. We consider steroids useful at
the very beginning of the disease, awaiting effectiveness of
DMARDs or of local injection; but this is not the method
utlilised by numerous colleagues. The last point (also shared
with the disease activity score) is that the locations of synovitis
of swollen joint(s) were not mentioned and could have made a
difference between experts' opinions, even if this possibility
seems low [18]. Indeed, one way to validate the proposition is
to apply it to our current own patients in real life. This validation
is ongoing with all of the panelists.
Conclusions
According to the presented results, the STPR group recom-
mends maintaining treatment without changing the molecule
or the dose regimen when a patient with stable clinical status
over the past 3 months has DAS28 ≤ 2.4. Above this thresh-
old, the number of swollen joints should be considered - inde-
pendently of or in addition to the DAS28 value - for the
clinician to make a decision to maintain or to change therapy.
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